Immunogenicity and safety of two-dose SARS-CoV-2 vaccination via different platforms in kidney transplantation recipients
After kidney transplantation, patients exhibit a poor response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. However, the efficacy and adverse effects of vaccines based on different platforms in these patients remain unclear. We prospectively analyzed both anti-spike p...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.951576/full |
| _version_ | 1818023008360464384 |
|---|---|
| author | Chien-Chia Chen Yi-Jen Huang Mei-Jun Lai Min-Huey Lin Wei-Chou Lin Hui-Ying Lin Yu-Chun Lin Yu-Tsung Huang Ya-Fen Lee Meng-Kun Tsai Meng-Kun Tsai Chih-Yuan Lee |
| author_facet | Chien-Chia Chen Yi-Jen Huang Mei-Jun Lai Min-Huey Lin Wei-Chou Lin Hui-Ying Lin Yu-Chun Lin Yu-Tsung Huang Ya-Fen Lee Meng-Kun Tsai Meng-Kun Tsai Chih-Yuan Lee |
| author_sort | Chien-Chia Chen |
| collection | DOAJ |
| description | After kidney transplantation, patients exhibit a poor response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. However, the efficacy and adverse effects of vaccines based on different platforms in these patients remain unclear. We prospectively analyzed both anti-spike protein antibody and cellular responses 1 month after the first and second doses of SARS-CoV-2 vaccines in 171 kidney transplant patients. Four vaccines, including one viral vector (ChAdOx1 nCov-19, n = 30), two mRNA (mRNA1273, n = 81 and BNT162b2, n = 38), and one protein subunit (MVC-COV1901, n = 22) vaccines were administered. Among the four vaccines, mRNA1273 elicited the strongest humoral response and induced the highest interferon-γ levels in patients with a positive cellular response against the spike protein. Antiproliferative agents were negatively associated with both the antibody and cellular responses. A transient elevation in creatinine levels was noted in approximately half of the patients after the first dose of mRNA1273 or ChadOx1, and only one of them presented with borderline cellular rejection without definite causality to vaccination. In conclusion, mRNA1273 had better immunogenicity than the other vaccines. Further, renal function needs to be carefully monitored after vaccination, and vaccination strategies should be tailored according to the transplant status and vaccine characteristics. |
| first_indexed | 2024-12-10T03:37:29Z |
| format | Article |
| id | doaj.art-6360d679b7bf4c718d7977520bd24a1c |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-10T03:37:29Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-6360d679b7bf4c718d7977520bd24a1c2022-12-22T02:03:40ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-09-011310.3389/fimmu.2022.951576951576Immunogenicity and safety of two-dose SARS-CoV-2 vaccination via different platforms in kidney transplantation recipientsChien-Chia Chen0Yi-Jen Huang1Mei-Jun Lai2Min-Huey Lin3Wei-Chou Lin4Hui-Ying Lin5Yu-Chun Lin6Yu-Tsung Huang7Ya-Fen Lee8Meng-Kun Tsai9Meng-Kun Tsai10Chih-Yuan Lee11Department of Surgery, National Taiwan University Hospital, Taipei, TaiwanDepartment of Pharmacy, National Taiwan University Hospital, Taipei, TaiwanDepartment of Laboratory Medicine, National Taiwan University Hospital, Taipei, TaiwanDepartment of Nursing, National Taiwan University Hospital, Taipei, TaiwanDepartment of Pathology, National Taiwan University Hospital, Taipei, TaiwanDepartment of Nursing, National Taiwan University Hospital, Taipei, TaiwanDepartment of Surgery, National Taiwan University Hospital, Taipei, TaiwanDepartment of Laboratory Medicine, National Taiwan University Hospital, Taipei, TaiwanDepartment of Laboratory Medicine, National Taiwan University Hospital, Taipei, TaiwanDepartment of Surgery, National Taiwan University Hospital, Taipei, TaiwanDivision of General Surgery, Department of Surgery, National Taiwan University Biomedical Park Hospital, National Taiwan University Hospital Hsinchu Branch, Hsinchu, TaiwanDepartment of Surgery, National Taiwan University Hospital, Taipei, TaiwanAfter kidney transplantation, patients exhibit a poor response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. However, the efficacy and adverse effects of vaccines based on different platforms in these patients remain unclear. We prospectively analyzed both anti-spike protein antibody and cellular responses 1 month after the first and second doses of SARS-CoV-2 vaccines in 171 kidney transplant patients. Four vaccines, including one viral vector (ChAdOx1 nCov-19, n = 30), two mRNA (mRNA1273, n = 81 and BNT162b2, n = 38), and one protein subunit (MVC-COV1901, n = 22) vaccines were administered. Among the four vaccines, mRNA1273 elicited the strongest humoral response and induced the highest interferon-γ levels in patients with a positive cellular response against the spike protein. Antiproliferative agents were negatively associated with both the antibody and cellular responses. A transient elevation in creatinine levels was noted in approximately half of the patients after the first dose of mRNA1273 or ChadOx1, and only one of them presented with borderline cellular rejection without definite causality to vaccination. In conclusion, mRNA1273 had better immunogenicity than the other vaccines. Further, renal function needs to be carefully monitored after vaccination, and vaccination strategies should be tailored according to the transplant status and vaccine characteristics.https://www.frontiersin.org/articles/10.3389/fimmu.2022.951576/fullSARS-CoV-2vaccinesplatformimmunogenicitykidney transplant |
| spellingShingle | Chien-Chia Chen Yi-Jen Huang Mei-Jun Lai Min-Huey Lin Wei-Chou Lin Hui-Ying Lin Yu-Chun Lin Yu-Tsung Huang Ya-Fen Lee Meng-Kun Tsai Meng-Kun Tsai Chih-Yuan Lee Immunogenicity and safety of two-dose SARS-CoV-2 vaccination via different platforms in kidney transplantation recipients Frontiers in Immunology SARS-CoV-2 vaccines platform immunogenicity kidney transplant |
| title | Immunogenicity and safety of two-dose SARS-CoV-2 vaccination via different platforms in kidney transplantation recipients |
| title_full | Immunogenicity and safety of two-dose SARS-CoV-2 vaccination via different platforms in kidney transplantation recipients |
| title_fullStr | Immunogenicity and safety of two-dose SARS-CoV-2 vaccination via different platforms in kidney transplantation recipients |
| title_full_unstemmed | Immunogenicity and safety of two-dose SARS-CoV-2 vaccination via different platforms in kidney transplantation recipients |
| title_short | Immunogenicity and safety of two-dose SARS-CoV-2 vaccination via different platforms in kidney transplantation recipients |
| title_sort | immunogenicity and safety of two dose sars cov 2 vaccination via different platforms in kidney transplantation recipients |
| topic | SARS-CoV-2 vaccines platform immunogenicity kidney transplant |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.951576/full |
| work_keys_str_mv | AT chienchiachen immunogenicityandsafetyoftwodosesarscov2vaccinationviadifferentplatformsinkidneytransplantationrecipients AT yijenhuang immunogenicityandsafetyoftwodosesarscov2vaccinationviadifferentplatformsinkidneytransplantationrecipients AT meijunlai immunogenicityandsafetyoftwodosesarscov2vaccinationviadifferentplatformsinkidneytransplantationrecipients AT minhueylin immunogenicityandsafetyoftwodosesarscov2vaccinationviadifferentplatformsinkidneytransplantationrecipients AT weichoulin immunogenicityandsafetyoftwodosesarscov2vaccinationviadifferentplatformsinkidneytransplantationrecipients AT huiyinglin immunogenicityandsafetyoftwodosesarscov2vaccinationviadifferentplatformsinkidneytransplantationrecipients AT yuchunlin immunogenicityandsafetyoftwodosesarscov2vaccinationviadifferentplatformsinkidneytransplantationrecipients AT yutsunghuang immunogenicityandsafetyoftwodosesarscov2vaccinationviadifferentplatformsinkidneytransplantationrecipients AT yafenlee immunogenicityandsafetyoftwodosesarscov2vaccinationviadifferentplatformsinkidneytransplantationrecipients AT mengkuntsai immunogenicityandsafetyoftwodosesarscov2vaccinationviadifferentplatformsinkidneytransplantationrecipients AT mengkuntsai immunogenicityandsafetyoftwodosesarscov2vaccinationviadifferentplatformsinkidneytransplantationrecipients AT chihyuanlee immunogenicityandsafetyoftwodosesarscov2vaccinationviadifferentplatformsinkidneytransplantationrecipients |